Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine

被引:2
|
作者
Liang, Henry [1 ,4 ]
Guo, Jessica [2 ]
Li, Chun Guang [3 ]
机构
[1] Western Sydney Univ, Campbelltown Campus, Artarmon, NSW, Australia
[2] Dr Henry Liang Clin, Artarmon, NSW, Australia
[3] Western Sydney Univ, NICM Hlth Res Inst, Penrith, NSW, Australia
[4] Dr Henry Liang Clin, Level 1, 66 Hampden Rd, Artarmon, NSW 2064, Australia
关键词
diffuse large B-cell lymphoma; double-hit lymphoma; complete remission; long term survival; Chinese herbal medicine; MULTICENTER;
D O I
10.1177/15347354221147515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Double-hit diffuse large B-cell lymphoma (DHL) is an uncommon subtype of lymphoma which poorly responds to current drug therapies and has low rates of long-term survival in the patients. Herein, we report a case of a 73-year-old Caucasian male who was diagnosed with DHL with double-hit mutations of rearrangement of both c-MYC and BCL2 in November 2013. He commenced the standard R-CHOP-14 chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) but changed to dose-adjusted DA-EPOCH-R protocol (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab) in the second and third cycles due to double-hit mutation. Because of intolerance to the intensive therapy, the patient decided to switch to Chinese medicine intervention. From March 2014 to December 2019, he was prescribed with a classical Chinese herbal formula-Sijunzi Decoction plus Prunella vulgaris based prescriptions. After 2 months of the Chinese herbal medicine intervention, the patient felt his right groin mass disappeared. Imaging follow-up showed no residual masses, and no lymphadenopathy was seen. During the period of Chinese herbal medicine treatment, his adherence and tolerability were well maintained with no adverse events. Imaging surveillances afterward found no evidence of lymphoma recurrence. His regular blood tests indicated that the patient's blood counts were normal and stable; no hematologic toxicity, hepatoxicity, or nephrotoxicity associated with Chinese herbal medicine were found. Follow-up visits until 2020 found that he had been living and enjoying a good quality of life for over 8 years post-diagnosis. This case study illustrates the potential values of Chinese herbal medicine in DHL treatment, alongside chemo-immunotherapy, and in maintaining long-term survival and satisfactory quality of life for DHL patients. The case report provides clinicians with preliminary evidence of the use of Chinese herbal medicine as a therapeutic strategy in the management of DHL.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Double-Hit Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3439 - 3443
  • [2] Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma
    Wu, Cheng-Han
    Gau, Jyh-Pyng
    Teng, Chieh-Lin Jerry
    Shih, Yu-Hsuan
    Su, Yu-Chen
    Wang, Ren-Ching
    Chen, Tsung-Chih
    DIAGNOSTICS, 2022, 12 (05)
  • [3] The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH
    Hilton, Laura K.
    Tang, Jeffrey
    Ben-Neriah, Susana
    Alcaide, Miguel
    Jiang, Aixiang
    Grande, Bruno M.
    Rushton, Christopher K.
    Boyle, Merrill
    Meissner, Barbara
    Scott, David W.
    Morin, Ryan D.
    BLOOD, 2019, 134 (18) : 1528 - 1532
  • [4] Double-hit primary cutaneous large B-cell lymphoma
    Nardini, N.
    Markiewicz, D.
    Calonje, E.
    VIRCHOWS ARCHIV, 2020, 477 : S246 - S246
  • [5] Durable Long-Term Response in a Patient With Diffuse Large B-Cell Lymphoma Treated With Nivolumab
    Ginnaram, Shravya R.
    Mason, Emily F.
    Reddy, Nishitha M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : E934 - E936
  • [6] Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report
    Valencia Castillo, Sandra Liliana
    Antonio Shally, Marcellini
    Tienza Ana, Torres
    Miguel Angel, Osorio Manyari
    Tapia Marta, Mosquera
    Montero Pablo, Jimenez
    Mateo Aranzazu, Garcia
    Alvarez Pilar, Galan
    Cornacchia Carmen, Olivier
    Jose Antonio, Queizan Hernandez
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S423 - S423
  • [7] miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy
    Montes-Moreno, Santiago
    Martinez, Nerea
    Sanchez-Espiridion, Beatriz
    Diaz Uriarte, Ramon
    Elena Rodriguez, Maria
    Saez, Anabel
    Montalban, Carlos
    Gomez, Gonzalo
    Pisano, David G.
    Fernando Garcia, Juan
    Conde, Eulogio
    Gonzalez-Barca, Eva
    Lopez, Andres
    Mollejo, Manuela
    Grande, Carlos
    Angel Martinez, Miguel
    Dunphy, Cherie
    Hsi, Eric D.
    Rocque, Gabrielle B.
    Chang, Julie
    Go, Ronald S.
    Visco, Carlo
    Xu-Monette, Zijun
    Young, Ken H.
    Piris, Miguel A.
    BLOOD, 2011, 118 (04) : 1034 - 1040
  • [8] Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement
    Sawada, Takeshi
    Omuro, Yasushi
    Kobayashi, Takeshi
    Hishima, Tunekazu
    Koizumi, Fumiaki
    Kanemasa, Yusuke
    Shimoyama, Tatsu
    Sasaki, Eisaku
    Maeda, Yoshiharu
    ONCOTARGETS AND THERAPY, 2014, 7 : 2133 - 2136
  • [9] Double-Hit Lymphoma - A Rare Subset of Diffuse Large B Cell Lymphoma with Poor Outcome
    Zaman, Sajid
    Gillani, Jawad A.
    Rasheed, Rashid
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2016, 26 (10): : 865 - 867
  • [10] The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH (vol 134, pg 1528, 2019)
    Hilton, L. K.
    Tang, J.
    Ben-Neriah, S.
    BLOOD, 2020, 135 (17) : 1507 - 1507